. Author manuscript; available in PMC: 2011 Jun 1.

Published in final edited form as: Cancer Prev Res (Phila). 2010 Apr 19;3(6):696–706. doi: 10.1158/1940-6207.CAPR-10-0076

Table 2.

Annual rates of invasive breast cancer—NSABP STAR Trial (P-2)

Participant characteristic at baseline	Number of events		Rate per 1000				RR (95%CI)
Participant characteristic at baseline	Tamoxifen	Raloxifene	Tamoxifen	Raloxifene	Difference^*	RR^†	RR (95%CI)
Age at entry (years)
≤ 49	10	15	1.84	2.80	−0.96	1.53	0.64–3.80
50–59	125	155	4.09	5.03	−0.94	1.23	0.97–1.57
≥ 60	112	140	4.47	5.48	−1.01	1.22	0.95–1.58
History of lobular carcinoma in situ
No	197	253	3.54	4.50	−0.96	1.27	1.05–1.54
Yes	50	57	9.14	10.34	−1.20	1.13	0.76–1.69
History of atypical hyperplasia
No	187	218	3.90	4.52	−0.62	1.16	0.95–1.42
Yes	60	92	4.58	6.79	−2.21	1.48	1.06–2.09
5-year predicted breast cancer risk (%)
≤ 3.00	61	81	2.39	3.21	−0.82	1.34	0.95–1.90
3.01–5.00	84	91	4.43	4.63	−0.20	1.05	0.77–1.42
≥ 5.01	102	138	6.13	8.17	−2.04	1.33	1.02–1.74
No. 1⁰ relatives with breast cancer
0	82	105	4.77	6.17	−1.40	1.29	0.96–1.75
1	112	135	3.51	4.10	−0.59	1.17	0.90–1.51
≥ 2	53	70	4.44	5.96	−1.52	1.34	0.93–1.96

Total	247	310	4.04	5.02	−0.98	1.24	1.05–1.47

Abbreviations: CI, confidence interval; NSABP STAR, National Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene; RR, risk ratio.

Rate in the tamoxifen group minus rate in the raloxifene group.

^†

Risk ratio for women in the raloxifene group compared to women in the tamoxifen group.